Complete metastasectomy in patients with stage IV metastatic melanoma

Lancet Oncology

Volumn 7, Issue 11, 2006, Pages 919-924

  Ollila, David W ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; CISPLATIN; DACARBAZINE; FLUORODEOXYGLUCOSE F 18; IMMUNOMODULATING AGENT; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ONAMELATUCEL L; PLACEBO; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; LIVER METASTASIS; LUNG EDEMA; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SHOCK; SKIN METASTASIS; SKIN SURGERY; SOFT TISSUE METASTASIS; SURVIVAL RATE; SYSTEMIC THERAPY; THORAX RADIOGRAPHY; TUMOR LOCALIZATION; VISCERAL METASTASIS;

HUMANS; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS;

EID: 33750364347     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70938-X     Document Type: Review

References (57)

1. Atkins M., Lotze M., Dutcher J., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 (1999) 2105-2116
2. Falkson C., Ibrahim J., Kirkwood J., et al. Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative oncology Group Study. J Clin Oncol 16 (1998) 1743-1751
3. Coates A., and Segelov E. Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol 5 (1994) 249-251
4. Greene F., Page D., Fleming I., et al. AJCC cancer staging manual. 6th edn. (2002), Springer-Verlag, New York
5. Morton D., Ollila D., Hsueh E., et al. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin 49 (1999) 101-116
6. Carbone P., and Costello W. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388). Cancer Treat Rep 60 (1976) 193-198
7. Hill II G., Krementz E., and Hill H. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma: IV-late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53 (1984) 1299-1305
8. Middleton M., Grob J., Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18 (2000) 158-166
9. Paul M., Summers Y., Calvert A., et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 12 (2002) 175-178
10. Rosenberg S., Yang J., Topalian S., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271 (1994) 907-913
11. Keilholz U., Goey S., Punt C., et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15 (1997) 2579-2588
12. Legha S., Ring S., Eton O., et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16 (1998) 1752-1759
13. Richards J., Gale D., Mehta N., and Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 17 (1999) 651-657
14. Legha S., Ring S., Bedikian A., et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 7 (1996) 827-835
15. Khayat D., Borel C., Tourani J., et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11 (1993) 2173-2180
16. Lewis K., Gibbs P., O'Day S., et al. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest 23 (2005) 303-308
17. Atkins M., Lee S., Flaherty L., et al. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon-alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 22 (2003) 708
18. Bajetta E., Del Vecchio M., Nova P., et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma. Ann Oncol 17 (2006) 571-577
19. Keilholz U., Punt C., Gore M., et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 20 (2005) 6747-6755
20. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1 (1889) 571-573
21. Ewing J. Neoplastic diseases: a treatise on tumors. 3rd edn. (1928), WB Saunders, Philadelphia
22. Harpole Jr. D., Johnson C., Wolfe W., et al. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 103 (1992) 743-748
23. The International Registry of Lung Metastases. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 113 (1997) 37-49
24. Ollila D., Essner R., Wanek L., and Morton D. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 131 (1996) 975-979
25. Essner R., Lee J., Wanek L., et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139 (2004) 961-966
26. Ollila D., and Morton D. Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin N Am 8 (1998) 183-196
27. Yasui K., and Shimizu Y. Surgical treatment for metastatic malignancies: anatomical resection of liver metastasis-indications and outcomes. Int J Clin Oncol 10 (2005) 86-96
28. Hofmann H., Neef H., Krohe K., et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48 (2005) 77-81
29. Inoue M., Ohta M., Iuchi K., et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 78 (2004) 238-244
30. Anraku M., Yokoi K., Nakagawa K., et al. Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients. J Thorac Cardiovasc Surg 127 (2004) 1107-1112
31. Balch C., Buzaid A., Soong S., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 (2001) 3635-3648
32. Balch C., Soong S., Gershenwald J., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
33. Barth A., Wanek L., and Morton D. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 181 (1995) 193-201
34. Gadd M., and Coit D. Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenectomy for melanoma. Arch Surg 127 (1992) 1412-1416
35. Feun L., Gutterman J., Burgess M., et al. The natural history of resectable metastatic melanoma (stage IV A melanoma). Cancer 50 (1982) 1656-1663
36. Balch C., Soong S., Murad T., et al. A multifactorial analysis of melanoma: IV-prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1 (1983) 126-134
37. Harris M., Berlangieri S., Cebon J., et al. Impact of 2-deoxy-2[F-18]fluoro-D-glucose positron emission tomography on the management of patients with advanced melanoma. Mol Imaging Biol 7 (2005) 304-308
38. 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?. J Nucl Med 45 (2004) 1323-1327
39. Eton O., Legha S., Moon T., et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16 (1998) 1103-1111
40. Markowitz J., Cosimi L., Carey R., et al. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 126 (1991) 703-707
41. Wong S., and Coit D. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 16 (2004) 155-160
42. Gorenstein L., Putnam J., Natarajan G., et al. Improved survival after resection of pulmonary metastases from malignant melanoma. Ann Thorac Surg 52 (1991) 204-210
43. Tafra L., Dale P., Wanek L., et al. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 110 (1995) 119-128
44. Leo F., Cagini L., Rocmans P., et al. Lung metastases from melanoma: when is surgical treatment warranted?. Br J Cancer 83 (2000) 569-572
45. Karp N., Boyd A., DePan H., et al. Thoracotomy for metastatic malignant melanoma of the lung. Surgery 107 (1990) 256-261
46. Karakousis C., Velez A., Driscoll D., and Takita H. Metastasectomy in malignant melanoma. Surgery 115 (1994) 295-302
47. La Hei E., Thompson J., McCaughan B., et al. Surgical resection of pulmonary metastatic melanoma: a review of 83 thoracotomies. Asia Pacific Heart J 5 (1996) 111-114
48. Das Gupta T., and Brasfield R. Metastatic melanoma of the gastrointestinal tract. Arch Surg 88 (1964) 969-973
49. Patel J., Didolkar M., Pickren J., and Moore R. Metastatic pattern of malignant melanoma: a study of 216 autopsy cases. Am J Surg 135 (1978) 807-810
50. de la Monte S., Moore G., and Hutchins G. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 43 (1983) 3427-3433
51. Ricaniadis N., Konstadoulakis M., Walsh D., and Karakousis C. Gastrointestinal metastases from malignant melanoma. Surg Oncol 4 (1995) 105-110
52. Agarwala S., Glaspy J., O'Day S., et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 20 (2002) 125-133
53. Branum G., Epstein R., Leight G., and Seigler H. The role of resection in the management of melanoma metastatic to the adrenal gland. Surgery 109 (1991) 127-131
54. Wood T., DiFronzo L., Rose D., et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival?. Ann Surg Oncol 8 (2001) 658-662
55. Agrawal S., Yao T., and Coit D. Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol 6 (1999) 336-344
56. Branum G., and Seigler H. Role of surgical intervention in the management of intestinal metastases from malignant melanoma. Am J Surg 162 (1991) 428-431
57. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, double-blind, phase 3 study of the specific active immunotherapy agent, onamelatucel-L (Canvaxin), compared to placebo as a post-surgical adjvuvant in AJCC stage IV melanoma: plenary talk. Society of Surgical Oncology Cancer Symposium, 59th Annual Meeting; March 24, 2006; San Diego, CA, USA.